W. pigra cDNA Clone Library (Multi-Anticoagulant)
Early W. pigra anticoagulant cDNA clones with hementin-like / saratin-like activities, compiled by Tang 2020.
Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Early W. pigra anticoagulant cDNA clones with hementin-like / saratin-like activities, compiled by Tang 2020.
- Evidence level
- Expert consensus
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
cDNA-clone-level identification does NOT establish clinical efficacy. No FDA-approved derivative; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Whitmania pigra
- Discovered
- 2020 · Tang X et al.
Biological Targets
- → thrombin; platelet aggregation; fibrinolysis enhancement (composite)
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.